Lynne Bingle

Dr. Lynne Bingle

University of Sheffield, Sheffield, UK
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2006 in Respiratory Research
Verified
Journal Article
Open access
LBLynne Bingle
Lynne Bingle
SCSimon Cross
Simon Cross
AHAlec S High
Alec S High
WWWilliam A Wallace
William A Wallace
DRDoris Rassl
Doris Rassl
CBColin Bingle
Colin Bingle
Background: The Whey Acidic Protein domain is an evolutionarily conserved motif found in a number of proteins, the best studied of which are antiproteinases involved in the innate immune defence of multiple epithelia. We recently characterised the WFDC2 gene which encodes a two WAP domain-containing protein, initially suggested as a marker for epididymis, and showed that it is highly expressed in the lung and salivary gland. The precise location of WFDC2 protein in these sites has not been described. Methods: We used immunohistochemistry to localise WFDC2 in normal tissues of the respiratory tract, naso- and oropharynx, as well as in chronically inflamed lung from Cystic Fibrosis and a range of pulmonary carcinomas. We have complemented these studies with molecular analysis of WFDC2 gene expression in primary human lung cell cultures. Results: WFDC2 is expressed in some epithelial cells of the upper airways as well as in mucous cells and ducts of submucosal glands. No staining was seen in peripheral lung. Intense staining is found in major salivary glands and in minor glands of the nose, sinuses, posterior tongue and tonsil. Studies with the related protein Secretory Leukocyte Protease Inhibitor (SLPI) show that although both proteins are expressed in similar tissues, the precise cellular localisation differs. Significant increases in expression and localisation of WFDC2 are seen in patients with Cystic Fibrosis. SLPI expression was greatly reduced in the same samples. In cultures of tracheobronchial epithelial cells, expression of WFDC2 and SLPI are differentially regulated during differentiation yet WFDC2 is not induced by pro-inflammatory mediators. The majority of adenocarcinomas stain with WFDC2 whilst a significant minority of squamous, small cell and large cell carcinomas exhibit focal staining. There is no clear association with tumour grade. Conclusion: We believe that these studies support the hypothesis that WFDC2 may be a component of the innate immune defences of the lung, nasal and oral cavities and suggest that WFDC2 functions in concert with related WAP domain containing proteins in epithelial host defence. We also suggest that WFDC2 re-expression in lung carcinomas may prove to be associated with tumour type and should be studied in further detail.

20 July 2011 in Biochemical Society Transactions
Verified
Journal Article
Closed access
PDF file
LBLynne Bingle
Lynne Bingle
CBColin Bingle
Colin Bingle
Although gene expression studies have shown that human PLUNC (palate, lung and nasal epithelium clone) proteins are predominantly expressed in the upper airways, nose and mouth, and proteomic studies have indicated they are secreted into airway and nasal lining fluids and saliva, there is currently little information concerning the localization of human PLUNC proteins. Our studies have focused on the localization of three members of this protein family, namely SPLUNC1 (short PLUNC1), SPLUNC2 and LPLUNC1 (long PLUNC1). Western blotting has indicated that PLUNC proteins are highly glycosylated, whereas immunohistochemical analysis demonstrated distinct patterns of expression. For example, SPLUNC2 is expressed in serous cells of the major salivary glands and in minor mucosal glands, whereas SPLUNC1 is expressed in the mucous cells of these glands. LPLUNC1 is a product of a population of goblet cells in the airway epithelium and nasal passages and expressed in airway submucosal glands and minor glands of the oral and nasal cavities. SPLUNC1 is also found in the epithelium of the upper airways and nasal passages and in airway submucosal glands, but is not co-expressed with LPLUNC1. We suggest that this differential expression may be reflected in the function of individual PLUNC proteins.

1 February 2005 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
LBLynne Bingle
Lynne Bingle
SCSimon Cross
Simon Cross
AHAlec S High
Alec S High
WWWilliam A Wallace
William A Wallace
DDDeirdre A Devine
Deirdre A Devine
CBColin Bingle
Colin Bingle

7 November 2007 in Respiratory Research
Verified
Journal Article
Open access
PDF file
LBLynne Bingle
Lynne Bingle
FBFrances A Barnes
Frances A Barnes
SCSimon Cross
Simon Cross
DRDoris Rassl
Doris Rassl
WWWilliam A Wallace
William A Wallace
CBColin Bingle
Colin Bingle
Short PLUNC1 (SPLUNC1) is the founding member of a family of proteins (PLUNCS) expressed in the upper respiratory tract and oral cavity, which may function in host defence. It is one of the most highly expressed genes in the upper airways and the protein has been detected in sputum and nasal secretions. The biology of the PLUNC family is poorly understood but in keeping with the putative function of the protein as an immune defence protein, a number of RNA and protein studies have indicated that SPLUNC1 is increased in inflammatory/infectious conditions such as Cystic Fibrosis (CF), COPD and allergic rhinitis.

5 June 2009 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
LBLynne Bingle
Lynne Bingle
FBFrances A. Barnes
Frances A. Barnes
HLHayley Lunn
Hayley Lunn
MMMaslinda Musa
Maslinda Musa
SWSteve Webster
Steve Webster
CBColin Bingle
Colin Bingle

30 September 2008 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
Pablo VargasPablo Vargas
Pablo Vargas
PSPm Speight
Pm Speight
CBCd Bingle
Cd Bingle
ABAw Barrett
Aw Barrett
LBLynne Bingle
Lynne Bingle